CareDx Inc - Asset Resilience Ratio
CareDx Inc (CDNA) has an Asset Resilience Ratio of 0.00% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See CDNA working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2012–2025)
This chart shows how CareDx Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see balance sheet size of CareDx Inc.
Liquid Assets Composition Over Time
This chart breaks down CareDx Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore CDNA long-term investments to assets to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: CareDx Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
CareDx Inc Industry Peers by Asset Resilience Ratio
Compare CareDx Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Chemclin Diagnostics Co. Ltd. A
SHG:688468 |
Diagnostics & Research | 15.34% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
|
Healius Ltd
AU:HLS |
Diagnostics & Research | 0.06% |
|
Scope Fluidics SA
WAR:SCP |
Diagnostics & Research | 16.51% |
|
RHYTHM Biosciences Ltd
AU:RHY |
Diagnostics & Research | 2.74% |
|
Guangzhou Kingmed Diagnostics Group Co Ltd
SHG:603882 |
Diagnostics & Research | 0.14% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
Annual Asset Resilience Ratio for CareDx Inc (2012–2025)
The table below shows the annual Asset Resilience Ratio data for CareDx Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 27.05% | $111.78 Million | $413.23 Million | -2.67pp |
| 2024-12-31 | 29.72% | $145.96 Million | $491.05 Million | -3.10pp |
| 2023-12-31 | 32.82% | $153.22 Million | $466.83 Million | -4.59pp |
| 2022-12-31 | 37.42% | $203.17 Million | $542.99 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $566.62 Million | -- |
| 2020-12-31 | 24.43% | $90.03 Million | $368.51 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $83.56 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $76.73 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $55.64 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $61.14 Million | -- |
| 2012-12-31 | 0.30% | $30.00K | $9.88 Million | -- |
About CareDx Inc
CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression profiling solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart tr… Read more